Moreover, compared with the control group, volasertib can increase the signal of M1 macrophages marker iNOS in the tumor region, which suggested that PLK1 inhibition could increase the M1 macrophages infiltration to glioma TIM (Figure 9M). The gene discussed is PLK1; the disease is glioma.